5-Year Followup of a Randomized Prospective Study Comparing Mitomycin C and Bacillus Calmette-Guerin in Patients With Superficial Bladder Carcinoma

Malmström, Per‐Uno; Wijkström, Hans; Lundholm, Carl; Wester, Kenneth; Busch, Christer; Norlén, Bo Johan

doi:10.1016/s0022-5347(01)61607-0

Cited by 231 publications

(81 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Malmstrom et al looked at MMC in patients who had failed BCG and reported a 19% 3-year disease-free rate among intermediate and high-risk patients. 141 Valrubicin, a semisynthetic analog of doxorubicin and lipid soluble anthracycline, has demonstrated antitumor activity in nonmuscle-invasive bladder cancer and was evaluated as treatment for patients with CIS who failed BCG treatment. 142 Ninety patients with recurrent CIS after BCG failure were given 6 weekly instillations of 800 mg of intravesical valrubicin; 21% of patients initially had a complete response, but at a median follow up of 30 months, 88% of patients recurred, and 56% of these patients went on to have a radical cystectomy of which 15% had pT3 disease at time of surgery.…”

Section: Nonmuscle-invasive Diseasementioning

confidence: 99%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

300

275

View full text Add to dashboard Cite

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.

show abstract

Section: Nonmuscle-invasive Diseasementioning

confidence: 99%

Bladder Cancer in 2010: How Far have We Come?

Jacobs¹,

Lee

Montie

2010

CA: A Cancer Journal for Clinicians

300

275

View full text Add to dashboard Cite

show abstract

“…Mitomycin, epidoxorubicin and doxorubicin have all shown to have beneficial effects, but the optimal instillation scheme remains to be defined (Malmstrom et al, 1999;Malmstrom, 2000). Similarly, the best treatment for patients who fail to respond to adjuvant intravesical treatment needs further investigation, but cytotoxic drugs could represent an interesting alternative to standard BCG therapy.…”

mentioning

confidence: 99%

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

et al. 2007

View full text Add to dashboard Cite

Intravesical gemcitabine (Gem) has shown promising activity against transitional cell carcinomas (TCC) of the bladder, with moderate urinary toxicity and low systemic absorption. The present phase II study evaluated the activity of biweekly intravesical treatment with Gem using a scheme directly derived from in vitro preclinical studies. Patients with Bacille Calmette-Guérin (BCG) -refractory Ta G3, T1 G1-3 TCC underwent transurethral bladder resection and then intravesical instillation with 2000 mg Gem diluted in 50 ml saline solution on days 1 and 3 for 6 consecutive weeks. Thirty-eight (95%) of the 40 patients showed persistent negative post-treatment cystoscopy and cytology 6 months after Gem treatment, while the remaining 2 patients relapsed at 5 and 6 months. At a median follow-up of 28 months, recurrences had occurred in 14 patients. Among these, four had downstaged (T) disease, three had a lower grade (G) lesion and three had a reduction in both T and G. Urinary and systemic toxicity was very low, with no alterations in biochemical profiles. In conclusion, biweekly instillation of Gem proved active in BCG-refractory Ta G3, T1 G1-3 TCC. Our results highlight the importance of preclinical studies using in vitro systems that adequately reproduce the conditions of intravesical clinical treatment to define the best therapeutic schedule.

show abstract

“…After an extensive preclinical evaluation and marker lesion study, two phase III trials evaluated the immediate use of apaziquone following TURBT for Ta/T1 disease. [40] These studies were designed to detect a 12% absolute difference between apaziquone and placebo in the primary endpoint (2-year recurrence rate) at 5% level of significance and powered at 80%. However, both trials with 6.6% (SPI-611) and 6.2% (SPI-612) reductions in recurrence rates when compared with the placebo groups failed to achieve this outcome.…”

Section: Checkpoint Inhibitorsmentioning

confidence: 99%

Alternative therapies in patients with non-muscle invasive bladder cancer

Şanlı

Lotan

2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized.

show abstract

5-Year Followup of a Randomized Prospective Study Comparing Mitomycin C and Bacillus Calmette-Guerin in Patients With Superficial Bladder Carcinoma

Abstract: Therapy with BCG was superior to mitomycin C for recurrence prophylaxis but no difference was found for progression and survival.

Cited by 231 publications

References 14 publications

Bladder Cancer in 2010: How Far have We Come?

Bladder Cancer in 2010: How Far have We Come?

Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study

Alternative therapies in patients with non-muscle invasive bladder cancer

Contact Info

Product

Resources

About